Tuberous sclerosis complex-associated renal angiomyolipomas: A single center study of 17 consecutive cases

Wang,Hang; Long,Qilai; Wang,Yiwei; Liu,Li; Zhou,Lin; Guo,Jianming

doi:10.3892/ol.2016.4766

Tuberous sclerosis complex-associated renal angiomyolipomas: A single center study of 17 consecutive cases

Authors:
- Hang Wang
- Qilai Long
- Yiwei Wang
- Li Liu
- Lin Zhou
- Jianming Guo
View Affiliations

Affiliations: Department of Urology, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China
Published online on: June 23, 2016 https://doi.org/10.3892/ol.2016.4766
Pages: 1501-1506

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the treatment options for patients with tuberous sclerosis complex (TSC)-associated renal angiomyolipomas (AMLs). A total of 17 patients who were consecutively diagnosed with TSC-associated renal AMLs at the Department of Urology of Zhongshan Hospital between 1998 and 2012 were included in the study. The patient cohort included 7 males and 10 females with a mean age of 37.6 years (range, 18‑62 years). A total of 12 patients were diagnosed with renal AML with TSC during physical examination (PE), while 5 patients were admitted to the Emergency Department of Zhongshan Hospital due to spontaneous rupture of renal AMLs. All renal lesions were examined by ultrasonography and abdominal computed tomography prior to treatment. The primary outcome measure was the kidney reservation rate (patients that had not received nephrectomies) in the rupture group and PE group. Both abdominal ultrasonography and CT revealed AMLs in all patients and the mean tumor size was 10.0±4.0 cm (range, 3.0‑17.5 cm). Overall, 9 patients underwent surgery, which included unilateral nephrectomy in 4 patients and unilateral partial nephrectomy/tumor enucleation in 5 patients. The remaining 8 patients received medical treatment. All patients were followed‑up for between 10 and 67 months. One patient succumbed as a result of multiple organ failure, which was caused by hypovolemic shock due to the spontaneous rupture of renal AML. The kidney reservation rate during surgery was 87.5% (7/8) in the PE group and 25% (1/4) in the spontaneous rupture group. The management of TSC‑associated renal AMLs differs from that of solitary sporadic AMLs. Surgical therapy is recommended following careful risk‑benefit analysis.

View Figures

View References

1	Winterkorn EB, Daouk GH, Anupindi S and Thiele EA: Tuberous sclerosis complex and renal angiomyolipoma: Case report and review of the literature. Pediatr Nephrol. 21:1189–1193. 2006. View Article : Google Scholar : PubMed/NCBI
2	Crino PB, Nathanson KL and Henske EP: The tuberous sclerosis complex. N Engl J Med. 355:1345–1356. 2006. View Article : Google Scholar : PubMed/NCBI
3	Bourneville DM: Tuberous sclerosis of the cerebral cortex: Intellectual disability and hemiplegic epilepsy. Arch Neurol (Paris). 1:81–91. 1880.(In French).
4	Borkowska J, Schwartz RA, Kotulska K and Jozwiak S: Tuberous sclerosis complex: Tumors and tumorigenesis. Int J Dermatol. 50:13–20. 2011. View Article : Google Scholar : PubMed/NCBI
5	Yates JR: Tuberous sclerosis. Eur J Hum Genet. 14:1065–1073. 2006. View Article : Google Scholar : PubMed/NCBI
6	Franz DN, Bissler JJ and McCormack FX: Tuberous sclerosis complex: Neurological, renal and pulmonary manifestations. Neuropediatrics. 41:199–208. 2010. View Article : Google Scholar : PubMed/NCBI
7	de Vries PJ, Whittemore VH, Leclezio L, Byars AW, Dunn D, Ess KC, Hook D, King BH, Sahin M and Jansen A: Tuberous sclerosis associated neuropsychiatric disorders (TAND) and the TAND Checklist. Pediatr Neurol. 52:25–35. 2015. View Article : Google Scholar : PubMed/NCBI
8	Rakowski SK, Winterkorn EB, Paul E, Steele DJ, Halpern EF and Thiele EA: Renal manifestations of tuberous sclerosis complex: Incidence, prognosis, and predictive factors. Kidney Int. 70:1777–1782. 2006. View Article : Google Scholar : PubMed/NCBI
9	Henske EP: Tuberous sclerosis and the kidney: From mesenchyme to epithelium and beyond. Pediatr Nephrol. 20:854–857. 2005. View Article : Google Scholar : PubMed/NCBI
10	O'Callaghan FJ, Noakes MJ, Martyn CN and Osborne JP: An epidemiological study of renal pathology in tuberous sclerosis complex. BJU Int. 94:853–857. 2004. View Article : Google Scholar : PubMed/NCBI
11	Shepherd CW, Gomez MR, Lie JT and Crowson CS: Causes of death in patients with tuberous sclerosis. Mayo Clin Proc. 66:792–796. 1991. View Article : Google Scholar : PubMed/NCBI
12	Dixon BP, Hulbert JC and Bissler JJ: Tuberous sclerosis complex renal disease. Nephron Exp Nephrol. 118:e15–e20. 2011. View Article : Google Scholar : PubMed/NCBI
13	Rabenou RA and Charles HW: Differentiation of sporadic versus tuberous sclerosis complex-associated angiomyolipoma. AJR Am J Roentgenol. 205:292–301. 2015. View Article : Google Scholar : PubMed/NCBI
14	Northrup H and Krueger DA: International Tuberous Sclerosis Complex Consensus Group: Tuberous sclerosis complex diagnostic criteria update: Recommendations of the 2012 Iinternational tuberous sclerosis complex consensus conference. Pediatr Neurol. 49:243–254. 2013. View Article : Google Scholar : PubMed/NCBI
15	Wang H, Zhou L, Guo J, Sun L, Long Q, Ma Y, Zhang L, Lin Z, Zhu T and Wang G: Mini-flank supra-12th rib incision for open partial nephrectomy compared with laparoscopic partial nephrectomy and traditional open partial nephrectomy. PloS One. 9:e891552014. View Article : Google Scholar : PubMed/NCBI
16	Ewalt DH, Sheffield E, Sparagana SP, Delgado MR and Roach ES: Renal lesion growth in children with tuberous sclerosis complex. J Urol. 160:141–145. 1998. View Article : Google Scholar : PubMed/NCBI
17	Steiner MS, Goldman SM, Fishman EK and Marshall FF: The natural history of renal angiomyolipoma. J Urol. 150:1782–1786. 1993.PubMed/NCBI
18	Malone MJ, Johnson PR, Jumper BM, Howard PJ, Hopkins TB and Libertino JA: Renal angiomyolipoma: 6 case reports and literature review. J Urol. 135:349–353. 1986.PubMed/NCBI
19	Curatolo P, Bombardieri R and Jozwiak S: Tuberous sclerosis. Lancet. 372:657–668. 2008. View Article : Google Scholar : PubMed/NCBI
20	Kothary N, Soulen MC, Clark TW, Wein AJ, Shlansky-Goldberg RD, Crino PB and Stavropoulos SW: Renal angiomyolipoma: Long-term results after arterial embolization. J Vasc Interv Radiol. 16:45–50. 2005. View Article : Google Scholar : PubMed/NCBI
21	Castle SM, Gorbatiy V, Ekwenna O, Young E and Leveillee RJ: Radiofrequency ablation (RFA) therapy for renal angiomyolipoma (AML): An alternative to angio-embolization and nephron-sparing surgery. BJU Int. 109:384–387. 2012. View Article : Google Scholar : PubMed/NCBI
22	Curatolo P and Moavero R: mTOR inhibitors in tuberous sclerosis complex. Curr Neuropharmacol. 10:404–415. 2012. View Article : Google Scholar : PubMed/NCBI
23	Budde K and Gaedeke J: Tuberous sclerosis complex-associated angiomyolipomas: Focus on mTOR inhibition. Am J Kidney Dis. 59:276–283. 2012. View Article : Google Scholar : PubMed/NCBI
24	Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, Schmithorst VJ, Laor T, Brody AS, Bean J, et al: Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 358:140–151. 2008. View Article : Google Scholar : PubMed/NCBI
25	Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, Sauter M, Nonomura N, Brakemeier S, de Vries PJ, et al: Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): A multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 381:817–824. 2013. View Article : Google Scholar : PubMed/NCBI
26	Davies DM, de Vries PJ, Johnson SR, McCartney DL, Cox JA, Serra AL, Watson PC, Howe CJ, Doyle T, Pointon K, et al: Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: A phase 2 trial. Clin Cancer Res. 17:4071–4081. 2011. View Article : Google Scholar : PubMed/NCBI